title: Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA afathi@partners.org.
authors.forename: Amir T
authors.initials: AT
authors.lastname: Fathi
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: William M
authors.initials: WM
authors.lastname: Lin
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: Tyler
authors.initials: T
authors.lastname: Durazzo
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: Adriano
authors.initials: A
authors.lastname: Piris
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: Hossein
authors.initials: H
authors.lastname: Sadrzadeh
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: Lindsay
authors.initials: L
authors.lastname: Bernardo
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: Darrel R
authors.initials: DR
authors.lastname: Borger
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: Steven L
authors.initials: SL
authors.lastname: McAfee
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: Daniela
authors.initials: D
authors.lastname: Kroshinsky
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
authors.forename: Yi-Bin
authors.initials: YB
authors.lastname: Chen
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D008297:Male; D009154:Mutation; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D012878:Skin Neoplasms / Q000139:chemically induced*; D000077157:Sorafenib; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3